Scientists elucidated the molecular architecture and kinetics preceding AML relapse by utilizing error-corrected next-generation sequencing in 74 AML patients relapsing after alloHCT evaluating 140 samples from peripheral blood collected 0.6 to 14 months before relapse.
[Blood]
